PDI, which long made its money helping drug companies outsource sales, is shipping off its banner business and shifting its focus to diagnostics.
Private equity giant TPG invested $75 million in Precision for Medicine, a recently formed company that partners with drugmakers to help them establish the value of in-development products.
Sun Pharmaceutical is reported to be in negotiations to buy Indian rival Intas Pharmaceuticals for as much as $2.3 billion, talks that Intas says are not happening.
It's been a banner year for pharma M&A, and German generics maker Dermapharm is wise to the trend. The company is planning a €1 billion ($1.1 billion) sale, attracting bids from private equity groups that are eager to hop on the dealmaking bandwagon.
Amgen, months removed from a landmark FDA approval in oncology, is buying further into viruses that can hunt and kill cancer within the body.
Bayer knows it needs more M&A if it wants to keep up in the rapidly consolidating OTC and animal health businesses. But it's not just looking for bolt-on deals.
Overseas acquisitions by Indian drugmakers were at a 5-year high this year and topped $1.5 million compared to just $251 million in 2014, according to a report by Livemint. Using data from VCCEdge, the report said the "sharp increase" in M&A deals was the result of consolidation in the U.S. generics market and a high-risk "appetite" by Indian companies.
Ever since Zimmer agreed to purchase Biomet for $13.4 billion in April 2014, the wait for takeover of Smith & Nephew has been on, with Stryker being the most likely acquirer. Rumors of an impending deal were just renewed by a StreetInsider report that Stryker has put an $18 billion offer for Smith & Nephew on the table, sending its stock up as much as 6%.
Whether it ends in a tie-up or not, Shire's 6-month pursuit of Baxalta is about to come to a close. That's the word from a Wall Street Journal source close to the deal, who told the newspaper the Dublin drugmaker expects to ink a pact or walk away "reasonably soon."
AMRI, a contract drugmaker returning to profitability after years of restructuring, bought a New Jersey testing firm for $54 million, expanding its stable of services.